Multi-omics analysis revealed potential use of immunotherapy and CDK4/6 inhibitors in intimal sarcoma
This study characterizes the distinct mutation landscape yet similar immune microenvironment of rare IS and AS. Given the frequent cell cycle dysregulation and the observed PD-L1 expression in a subset of patients, CDK4/6 inhibitors and PD-1/PD-L1 inhibitors warrant further clinical investigation for these patients.
Authors
- Dingrong Zhong (ORCID: https://orcid.org/0000-0002-6229-1830)
- Ziyi Chang
- Huan Yin (ORCID: https://orcid.org/0009-0001-0800-8651)
- Bei Wang (ORCID: https://orcid.org/0000-0002-0595-8053)
- Yao Liu (ORCID: https://orcid.org/0000-0002-2775-1643)
- Rongrong Chen (ORCID: https://orcid.org/0000-0002-4489-4179)
- Feng Li (ORCID: https://orcid.org/0000-0002-8966-5505)
Institutions
- Beijing Chao-Yang Hospital, Capital Medical University (CN)
- China-Japan Friendship Hospital (CN)
- Inceptus (United States) (US)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-10-30
- DOI
- https://doi.org/10.3389/fimmu.2025.1668537
- Citations
- 1
- Primary Topic
- Gastrointestinal Tumor Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.81